SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 409.93 |
| Enterprise Value ($M) | 810.37 |
| Book Value ($M) | -182.61 |
| Book Value / Share | -3.14 |
| Price / Book | -2.24 |
| NCAV ($M) | -325.57 |
| NCAV / Share | -5.61 |
| Price / NCAV | -1.26 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.65 |
| Return on Assets (ROA) | -0.36 |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.69 |
| Current Ratio | 1.69 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 134.12 |
| Assets | 277.08 |
| Liabilities | 459.69 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -169.26 |
| Net Income | -156.81 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -148.80 |
| Cash from Investing | 82.22 |
| Cash from Financing | 62.88 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Ingalls & Snyder Llc | 7.20 | -6.09 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 223,961 | 1,086,469 | 20.61 | |
| 113,912 | 732,982 | 15.54 | |
| 185,111 | 1,136,783 | 16.28 | |
| 795,285 | 1,436,782 | 55.35 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| OCS – Oculis Holding AG | OCUL – Ocular Therapeutix, Inc. |
| OKUR – OnKure Therapeutics, Inc. | PAHC – Phibro Animal Health Corporation |
| PTGX – Protagonist Therapeutics, Inc. |